Does the media prefer GMAB or MIRM?

In the previous week, Genmab A/S had 17 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 23 mentions for Genmab A/S and 6 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.90 beat Genmab A/S's score of 0.25 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 3 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer UTHR or MIRM?

In the previous week, United Therapeutics had 12 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 18 mentions for United Therapeutics and 6 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.90 beat United Therapeutics' score of 0.43 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 5 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EXEL or MIRM?

In the previous week, Exelixis had 3 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 9 mentions for Exelixis and 6 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.90 beat Exelixis' score of 0.63 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ASND or MIRM?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 2 mentions for Ascendis Pharma A/S. Mirum Pharmaceuticals' average media sentiment score of 0.90 beat Ascendis Pharma A/S's score of 0.25 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MIRM or SMMT?

In the previous week, Summit Therapeutics had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 7 mentions for Summit Therapeutics and 6 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.90 beat Summit Therapeutics' score of 0.26 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Mirum Pharmaceuticals (MIRM) Competitors

$86.01 +4.66 (+5.73%)

Closing price 04:00 PM Eastern

Extended Trading

$85.98 -0.04 (-0.04%)

As of 07:41 PM Eastern

Compare

MIRM vs. GMAB, UTHR, EXEL, ASND, and SMMT

Should you buy Mirum Pharmaceuticals stock or one of its competitors? Mirum Pharmaceuticals's main competitors and comparable companies include Genmab A/S (GMAB), United Therapeutics (UTHR), Exelixis (EXEL), Ascendis Pharma A/S (ASND), and Summit Therapeutics (SMMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mirum Pharmaceuticals compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, Genmab A/S had 17 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 23 mentions for Genmab A/S and 6 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.90 beat Genmab A/S's score of 0.25 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 19.08% compared to Mirum Pharmaceuticals' net margin of -139.18%. Genmab A/S's return on equity of 14.89% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	6.05	$963M	$1.27	28.39
Mirum Pharmaceuticals	$521.31M	10.13	-$23.36M	-$14.55	N/A

Genmab A/S has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Genmab A/S presently has a consensus price target of $42.50, suggesting a potential upside of 17.89%. Mirum Pharmaceuticals has a consensus price target of $143.81, suggesting a potential upside of 76.78%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Genmab A/S beats Mirum Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

94.1% of United Therapeutics shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

United Therapeutics presently has a consensus price target of $627.31, indicating a potential upside of 17.74%. Mirum Pharmaceuticals has a consensus price target of $143.81, indicating a potential upside of 76.78%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, United Therapeutics had 12 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 18 mentions for United Therapeutics and 6 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.90 beat United Therapeutics' score of 0.43 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	5 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 41.56% compared to Mirum Pharmaceuticals' net margin of -139.18%. United Therapeutics' return on equity of 20.18% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

United Therapeutics has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.18	$1.33B	$27.95	19.06
Mirum Pharmaceuticals	$521.31M	10.13	-$23.36M	-$14.55	N/A

Summary

United Therapeutics beats Mirum Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

In the previous week, Exelixis had 3 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 9 mentions for Exelixis and 6 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.90 beat Exelixis' score of 0.63 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis currently has a consensus price target of $50.36, suggesting a potential downside of 14.68%. Mirum Pharmaceuticals has a consensus price target of $143.81, suggesting a potential upside of 76.78%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Exelixis has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.30	$782.57M	$3.18	18.56
Mirum Pharmaceuticals	$521.31M	10.13	-$23.36M	-$14.55	N/A

85.3% of Exelixis shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to Mirum Pharmaceuticals' net margin of -139.18%. Exelixis' return on equity of 42.17% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Exelixis has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Summary

Exelixis beats Mirum Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Ascendis Pharma A/S has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 2 mentions for Ascendis Pharma A/S. Mirum Pharmaceuticals' average media sentiment score of 0.90 beat Ascendis Pharma A/S's score of 0.25 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has lower revenue, but higher earnings than Ascendis Pharma A/S. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.05	-$258M	$12.89	17.28
Mirum Pharmaceuticals	$521.31M	10.13	-$23.36M	-$14.55	N/A

Ascendis Pharma A/S has a net margin of 70.99% compared to Mirum Pharmaceuticals' net margin of -139.18%. Ascendis Pharma A/S's return on equity of 32.54% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Ascendis Pharma A/S presently has a consensus price target of $310.75, suggesting a potential upside of 39.54%. Mirum Pharmaceuticals has a consensus price target of $143.81, suggesting a potential upside of 76.78%. Given Mirum Pharmaceuticals' higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Ascendis Pharma A/S beats Mirum Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Summit Therapeutics?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Mirum Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, meaning that its share price is 251% less volatile than the broader market.

4.6% of Summit Therapeutics shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Summit Therapeutics had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 7 mentions for Summit Therapeutics and 6 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.90 beat Summit Therapeutics' score of 0.26 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	10.13	-$23.36M	-$14.55	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Mirum Pharmaceuticals presently has a consensus price target of $143.81, indicating a potential upside of 76.78%. Summit Therapeutics has a consensus price target of $28.61, indicating a potential upside of 66.61%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

Summit Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Summit Therapeutics	N/A	-168.94%	-141.92%

Summary

Mirum Pharmaceuticals beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Mirum Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRM vs. The Competition

Export

Metric	Mirum Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.28B	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	20.71%
P/E Ratio	-5.91	13.42	274.13	26.16
Price / Sales	10.71	1,212.26	581.78	94.37
Price / Cash	1,595.75	116.56	76.38	53.09
Price / Book	14.05	17.17	11.21	6.34
Net Income	-$23.36M	-$22.69M	$3.50B	$381.90M
7 Day Performance	3.71%	-1.20%	-0.84%	-1.39%
1 Month Performance	-12.50%	-9.68%	-5.42%	-4.31%
1 Year Performance	16.51%	10.09%	4.38%	-0.35%

Mirum Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRM Mirum Pharmaceuticals	3.0822 of 5 stars	$86.01 +5.7%	$143.81 +67.2%	+11.7%	$5.28B	$521.31M	N/A	433	Analyst Forecast
GMAB Genmab A/S	4.0679 of 5 stars	$35.67 +0.3%	$39.50 +10.7%	+10.1%	$22.20B	$3.72B	28.09	3,029	Analyst Forecast Analyst Revision High Trading Volume
UTHR United Therapeutics	3.8818 of 5 stars	$541.89 +12.5%	$621.00 +14.6%	+18.7%	$20.65B	$3.18B	19.39	1,400	Analyst Forecast Insider Trade High Trading Volume
EXEL Exelixis	2.4643 of 5 stars	$58.41 -0.4%	$50.29 -13.9%	+52.7%	$14.53B	$2.32B	18.37	1,077	Trending News Analyst Forecast Analyst Revision
ASND Ascendis Pharma A/S	4.7897 of 5 stars	$227.83 -0.1%	$310.75 +36.4%	+6.0%	$14.23B	$814.57M	17.67	1,189

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRM) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. GMAB, UTHR, EXEL, ASND, and SMMT

How does Mirum Pharmaceuticals compare to Genmab A/S?

Summary

How does Mirum Pharmaceuticals compare to United Therapeutics?

Summary

How does Mirum Pharmaceuticals compare to Exelixis?

Summary

How does Mirum Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Mirum Pharmaceuticals compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. GMAB, UTHR, EXEL, ASND, and SMMT

How does Mirum Pharmaceuticals compare to Genmab A/S?

Does the media prefer GMAB or MIRM?

Is GMAB or MIRM more profitable?

Do insiders & institutionals hold more shares of GMAB or MIRM?

Which has stronger earnings & valuation, GMAB or MIRM?

Which has more risk & volatility, GMAB or MIRM?

Do analysts prefer GMAB or MIRM?

Summary

How does Mirum Pharmaceuticals compare to United Therapeutics?

Do insiders and institutionals believe in UTHR or MIRM?

Which has more risk and volatility, UTHR or MIRM?

Do analysts prefer UTHR or MIRM?

Does the media prefer UTHR or MIRM?

Is UTHR or MIRM more profitable?

Which has higher valuation and earnings, UTHR or MIRM?

Summary

How does Mirum Pharmaceuticals compare to Exelixis?

Does the media favor EXEL or MIRM?

Do analysts recommend EXEL or MIRM?

Which has better valuation and earnings, EXEL or MIRM?

Do insiders & institutionals hold more shares of EXEL or MIRM?

Is EXEL or MIRM more profitable?

Which has more volatility & risk, EXEL or MIRM?

Summary

How does Mirum Pharmaceuticals compare to Ascendis Pharma A/S?

Which has more volatility & risk, ASND or MIRM?

Does the media refer more to ASND or MIRM?

Which has higher valuation and earnings, ASND or MIRM?

Is ASND or MIRM more profitable?

Do analysts rate ASND or MIRM?

Summary

How does Mirum Pharmaceuticals compare to Summit Therapeutics?

Which has more volatility & risk, MIRM or SMMT?

Do insiders & institutionals believe in MIRM or SMMT?

Does the media refer more to MIRM or SMMT?

Which has preferable valuation and earnings, MIRM or SMMT?

Do analysts prefer MIRM or SMMT?

Is MIRM or SMMT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools